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Abstract
Autonomic dysfunction is observed in many cardiovascular diseases and contributes to cardiac remodeling and heart
disease. We previously reported that a decrease in the expression levels of the vesicular acetylcholine transporter (VAChT) in
genetically-modified homozygous mice (VAChT KDHOM) leads to decreased cholinergic tone, autonomic imbalance and a
phenotype resembling cardiac dysfunction. In order to further understand the molecular changes resulting from chronic
long-term decrease in parasympathetic tone, we undertook a transcriptome-based, microarray-driven approach to analyze
gene expression changes in ventricular tissue from VAChT KDHOM mice. We demonstrate that a decrease in cholinergic tone
is associated with alterations in gene expression in mutant hearts, which might contribute to increased ROS levels observed
in these cardiomyocytes. In contrast, in another model of cardiac remodeling and autonomic imbalance, induced through
chronic isoproterenol treatment to increase sympathetic drive, these genes did not appear to be altered in a pattern similar
to that observed in VAChT KDHOM hearts. These data suggest the importance of maintaining a fine balance between the two
branches of the autonomic nervous system and the significance of absolute levels of cholinergic tone in proper cardiac
function.
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Introduction
In many cardiovascular diseases an over-activation of sympa-
thetic tone coupled with a decrease in parasympathetic tone is
observed [1,2,3]. This leads to an imbalance between the two
branches of the autonomic nervous system (ANS) that seem to
contribute to cardiac remodeling. The ANS is the main regulator
of cardiac output and, as such, plays a vital role in maintaining
proper heart function. Recently, we reported that a systemic
reduction in the vesicular acetylcholine transporter (VAChT; [4]),
the protein responsible for packaging ACh into synaptic vesicles at
parasympathetic nerve terminals, leads to a phenotype which
resembles cardiac dysfunction in mice [5]. The mutant hearts have
altered calcium handling and show changes in myocyte contrac-
tility, causing decreased left ventricular fractional shortening in the
VAChT mutant mice [5]. Furthermore, these pathological
changes can be reversed through treatment with pyridostigmine,
a peripheral cholinesterase inhibitor, thus suggesting that cardiac
dysfunction in these mice results from a reduction in cholinergic
tone [5].
These results are in agreement with a number of recent
publications which indicate that increased levels of ACh can be
protective and increase survival in experimental models of heart
failure. For example, vagal stimulation improves outcome in
experimental models of heart failure in rats [6]. It has also been
reported that chronic treatment with the cholinesterase inhibitor
donepezil, an anti-Alzheimer’s drug, can reduce both cardiac
hypertrophy and remodeling and increase survival rates in rat and
mouse models of heart failure [7,8]. Acetylcholine, released from
vagal nerve terminals, has also been shown to have cardioprotec-
tive effects through its ability to activate the phosphatidylinositol-3-
kinase (PI3K)-Akt pathway [6]. Moreover, a switch to a
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cholinergic phenotype occurs in sympathetic terminals in mice as
well as in humans in heart failure and genetic inhibition of this
transdifferentiation in mice worsens outcomes in experimental
heart failure [9]. Hence, whereas higher levels of acetylcholine
seem to be cardioprotective, lower levels are usually related to
increased heart dysfunction.
In order to gain insight into potential molecular changes that
may occur in the heart under conditions of chronically decreased
cholinergic neurotransmission, we undertook a microarray-driven,
transcriptome-based analysis of hearts from VAChT KDHOM and
wild-type (WT) mice. Our goal was to determine whether long-
term decrease in ACh levels leads to alterations in gene expression
profiles that could contribute to heart dysfunction.
We demonstrate here that chronic reduction in cholinergic
neurotransmission in VAChT mutant mice is associated with
altered gene expression in the heart. Of the changes observed,
increased levels of the enzyme purine nucleoside phosphorylase
could contribute to increased reactive oxygen species (ROS) levels.
We found indeed that cardiomyocytes of mutant mice present an
increase in ROS. Interestingly, we demonstrate that the alterations
in gene expression observed in ventricles from VAChT mutant
mice are distinct from those observed in a model of cardiac
dysfunction with increased sympathetic drive, indicating the
Figure 1. qPCR analysis confirms the expression pattern of several genes detected in the microarray analysis. mRNA expression of
tRNA splicing endonuclease 3 (Tsen15; panel a), Growth arrest specific 5 (Gas5; panel b), karyopherin alpha 2 (Kpna2; panel c) and suppressor of
cytokine signaling 4 (Socs4; panel d) was increased in mutant mice. mRNA analysis of ribonuclease, RNase A family 4 (Rnase4; panel e) and
oxoglutarate-dehydrogenase like (Ogdhl; panel f) confirmed transcriptional downregulation in whole heart RNA from the mutant animals. Data
represent the mean 6 SEM, with n indicated within bars. *p,0.05 versus wild-type mice.
doi:10.1371/journal.pone.0039997.g001
Heart mRNA Analysis under Reduced Cholinergic Tone
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importance of absolute levels of cholinergic tone in regulating
cardiac function.
Methods
Animal Models and Drug Administration
VAChT KDHOM mice were generated as previously described
[4]. Three-month old male wild-type (WT) and VAChT mutant
mice in a mixed C57BL6/j background (backcrossed for 3
generations only, as further backcrossing onto the C57BL6/j
background causes infertility in this genotype) were used for all of
the experiments. Mice were housed in groups of 4 per cage in a
temperature-controlled room with a 12/12 light/dark cycle. Food
and water were provided ad libitum.
For the isoproterenol infusion experiments, 3-month-old male
wild-type mice from the colony were treated with isoproterenol
(Sigma-Aldrich, Mississauga, Canada) at a dose of 60 mg/kg/day
or saline for two weeks using the Alzet Osmotic Pumps (Model
2002, Durect Corporation, USA) and maintained in the Animal
Care Facility for an additional two weeks. All animals used in these
studies were maintained at the University of Western Ontario
(UWO, London, Canada) and experiments were performed
following the guidelines and protocols approved by the University
Council on Animal Care (UCAC) for animal research.
RNA Microarray Analysis
All sample labelling and GeneChip processing was performed
at the London Regional Genomics Centre (Robarts Research
Institute, London, Ontario, Canada; http://www.lrgc.ca). RNA
quality was assessed using the Agilent 2100 Bioanalyzer (Agilent
Technologies Inc., Palo Alto, CA) and the RNA 6000 Nano kit
(Caliper Life Sciences, Mountain View, CA). Single stranded
complimentary DNA (cDNA) was prepared from 2.0 mg
(ventricle extracts) of total RNA as per the Affymetrix
GeneChip Whole Transcript (WT) Sense Target Labeling Assay
Manual (Affymetrix, Santa Clara, CA). 5.5 mg of single stranded
DNA was synthesized, end labeled and hybridized, for 16 hours
at 45uC, to Mouse Gene 1.0 ST arrays to probe a set of 33,000
genes. All liquid handling steps were performed by a GeneChip
Fluidics Station 450 and GeneChips were scanned with the
GeneChip Scanner 3000 7G (Affymetrix, Santa Clara, CA)
using Command Console v1.1. Probes were summarized to
gene level data in Partek Genomics Suite v6.5 (Partek, St.
Louis, MO) using the RMA algorithm [10]. Partek was used to
determine gene level ANOVA p-values, fold changes and GO
(Gene Ontology) enrichment, using a Fisher’s exact test.
Differentially expressed genes were selected based on an
ANOVA p-value of less than 0.05 and 1.3 fold increase or
decrease between WT and KD samples. The data discussed in
this publication have been deposited in NCBI’s Gene Expres-
Figure 2. Purine nucleoside phosphorylases are upregulated in the hearts of VAChT KDHOMmice. mRNA expression of purine nucleoside
phosphorylase (Pnp; panel a) and purine nucleoside phosphorylase 2 (Pnp2, panel b) were upregulated. Pnp/Pnp2 protein content appears to
upregulated in VAChT KDHOM animals as compared to wild-type mice (panel c). Data represent the mean 6 SEM, with n indicated within bars.
*p,0.05 versus wild-type mice.
doi:10.1371/journal.pone.0039997.g002
Heart mRNA Analysis under Reduced Cholinergic Tone
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sion Omnibus and are accessible through GEO Series accession
number GSE37458 (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc =GSE37458).
Quantitative RT-PCR
Total RNA was extracted using the Fatty and Fibrous Tissue
RNA Extraction Kit (Bio-Rad Laboratories, Mississauga, Can-
ada) according to the manufacturer’s protocol. Total RNA from
whole hearts was eluted in 80 ml of Elution Solution.
Quantification and quality analysis of RNA in the extracted
samples was done by microfluidic analysis using the Agilent
2100 Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA). All
RNA samples used for the reverse transcription reaction had an
RNA integrity number of $8.0. 20 ml of cDNA was synthesized
from 500 ng of total RNA using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Streetsville,
Canada) following the manufacturer’s instructions. cDNA was
subsequently subjected to qPCR on a CFX-96 Real Time
System (Biorad) using the iQ SYBR GREEN SUPERMIX
(Biorad). The PCRs were cycled 40 times after initial
denaturation (95uC, 3 min) with the following parameters:
95uC for 10 s, annealing and extension at 60uC for 30 s. For
each experiment, a non-template reaction was used as a
negative control. Relative quantification of gene expression
was done with the DDCT method using b-actin gene expression
to normalize the data. All primers used for qPCR were
validated before use to confirm that efficiency was within the
required range. Sequences of primers used are available upon
request.
Immunoblotting
Whole hearts were placed in modified ice-cold RIPA buffer and
homogenized using a motorized Dounce homogenizer. 40–80 mg
of protein lysates were separated using SDS-PAGE and transferred
onto PVDF membranes. Antibodies, dilutions and their sources
are as follows: anti-acetyl-CoA carboxyase (1:1000; Cell Signal-
ing), anti-ATP citrate lyase (1:1000; Cell Signaling), anti-fatty acid
synthase (1:1000; Cell Signaling), anti-purine nucleoside phos-
phorylase (1:200; Santa Cruz Biotechnology), anti-a-tubulin
(1:3000; Sigma-Aldrich), and anti-a-actinin (1:2000; Sigma-
Aldrich). a-tubulin or a-actinin was used as a loading control for
all samples and the protein was quantified using densitometry
analysis.
Cardiomyocyte Isolation
Adult ventricular myocytes were isolated as previously described
[11]. Briefly, hearts were rapidly removed and perfused via the
Langendorff method with Ca2+-free modified Tyrode solution
until the blood was cleared. Hearts were then perfused with
Tyrode solution containing 100 mM CaCl2 along with 1.4 mg/ml
collagenase (type 2; Worthington, Lakewood, NJ) and 0.04 mg/ml
protease (type XIV; Sigma, St. Louis, MO) until they were soft
(,10 min). The hearts were removed from the perfusion
apparatus, minced into ,1- mm chunks, and stirred for 4 min
in Tyrode solution containing 0.1 mM CaCl2, 0.7 mg/ml
collagenase, and 0.02 mg/ml protease. Cells were filtered through
a 200- mm mesh to remove tissue chunks, and extracellular Ca2+
concentration was raised to 0.5 mM over 10 min through three
centrifuge cycles.
ROS Measurements
MitoSOX Red (Invitrogen) was used to measure mitochondrial
reactive oxygen species (ROS) production. Isolated cardiomyo-
cytes were loaded with MitoSOX Red (3 mmol/l) in DMEM for
20 min at room temperature, followed by washout. Confocal
images were obtained by excitation at 514 nm and measuring the
emitted light at 585 nm in cardiomyocytes bathed in normal
Tyrode’s solution. The confocal imaging was performed with a
Zeiss LSM 510META confocal microscope (CEMEL-Confocal
Microscopy Facility, ICB/UFMG).
Statistical Analyses
Results of qPCR, immunoblotting and MitoSOX experiments
are provided as mean 6 SEM. The student’s t-test was used to
assess statistical differences between two experimental groups
using SigmaStat software. P,0.05 was considered statistically
significant.
Results
Analysis of Transcriptional Alterations in VAChT KDHOM
Hearts
We have previously demonstrated that VAChT KDHOM mice
with reduced cholinergic neurotransmission develop cardiac
dysfunction [5]. To determine the transcriptional alterations in
VAChT mutant mice, we performed a microarray analysis using
Figure 3. VAChT KDHOM cardiomyocytes show increased levels of ROS. Isolated cardiomyocytes loaded with a MitoSOX superoxide indicator
reveal greater ROS levels in mutant myocytes (sample image; panel a). A robust, significant increase in fluorescence was observed in the KD
cardiomyocytes as compared to wild-type control cells (panel b). Data represent the mean6 SEM, with n indicated within bars. *p,0.05 versus wild-
type mice. Scale bar = 10 mm.
doi:10.1371/journal.pone.0039997.g003
Heart mRNA Analysis under Reduced Cholinergic Tone
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total RNA isolated from ventricles obtained from VAChT
KDHOM and age-matched WT mice. Ventricular tissue was used
for the microarray analysis due to the fact that the previous
experiments with these mice revealed major alterations related to
cardiac dysfunction in isolated, ventricular cardiomyocytes [5].
Therefore, we wanted to determine whether there were any
changes in gene expression in ventricular tissue that may
contribute to this dysfunction. A list of differentially expressed
genes was generated by limiting the fold change to at least 1.3 with
a significance of p#0.05 (Table S1). The gene ontology (GO)
analysis did not reveal robust alterations in any specific pathway in
the mutant ventricles. However, a total of 71 genes showed
differential expression between VAChT KDHOM and WT mice, of
which 52 genes were significantly up-regulated and 19 down-
regulated.
To examine the robustness of our microarray results, we
performed quantitative real-time PCR (qPCR) on four randomly
chosen genes which demonstrated a significant increase (Tsen15,
Gas5, Kpna2, Socs4) and two genes which demonstrated a
significant decrease (Rnase4, Ogdhl) in the microarray analysis.
The qPCR results confirmed that the expression of Tsen15, Gas5,
Kpna2 and Socs4 were significantly increased and that of Rnase4
and Ogdhl were significantly decreased in the ventricles obtained
from VAChT KDHOM mice (Figure 1), a result which confirms
our microarray data. Further analysis of the ventricular micro-
array suggested a significant upregulation in the expression of two
purine nucleoside phosphorylases, Pnp and Pnp2. Both Pnp and
Pnp2 are involved in generating hypoxanthine, a metabolite of
adenosine [12]. Hypoxanthine, produced in endothelial cells, has
been shown to translocate to myocytes [13,14] and contribute to
production of oxygen free radicals following further metabolism to
xanthine and urate [15,16,17,18]. Several studies have previously
shown that increased ROS levels can play a major role in cardiac
dysfunction in different cardiomyopathies Therefore, due to the
potential role of these enzymes in contributing to cardiac
malfunction in VAChT KDHOM mice, the increased expression
of these enzymes was further confirmed via qPCR (Figure 2a,
2b). Importantly, this transcriptional upregulation in Pnp/Pnp2
led to a significant increase in the protein content of Pnp/Pnp2 in
ventricular tissues obtained from VAChT mutant mice
(Figure 2c).
Mitochondrial Superoxide Levels are Increased in VAChT
KDHOM Animals
The increased expression of Pnp/Pnp2 in the hearts of mutant
mice might predict a greater production of ROS (as determined
via superoxide formation) in these mice. Interestingly, cardiomy-
ocytes from VAChT KDHOM hearts showed a significant increase
in superoxide levels as compared to wild-type control cells
(Figure 3), suggesting greater levels of ROS production in
VAChT KD cardiomyocytes as compared to WT mice.
Figure 4. The transcription of genes related to fatty acid biosynthesis is upregulated. mRNA expression of ATP citrate lyase (ACLY, panel
a), Acetyl-CoA carboxylase (ACC; panel b) and fatty acid synthase (FAS; panel c) was increased expression in VAChT KDHOM mice. Data represent the
mean 6 SEM, with n indicated within bars. *p,0.05 versus wild-type mice.
doi:10.1371/journal.pone.0039997.g004
Heart mRNA Analysis under Reduced Cholinergic Tone
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Lipid Biosynthesis Appears to be Unaltered in VAChT
KDHOM Mice
In addition to changes in ROS, which may contribute to
phenotype in these mice, previous work has suggested a decrease
in fatty acid oxidation during heart failure can also contribute to
further decline in cardiac function [19,20,21,22]. In order to
examine potential other changes in transcripts that could affect
cardiac energetics in the VAChT mutant mice, we used a
candidate gene approach and analyzed specific genes involved in
the lipid biosynthetic process. In particular, we studied the
expression of ATP citrate lyase (ACLY), acetyl-CoA carboxylase
(ACC) and fatty acid synthase (FAS). These genes, related to
cardiac metabolism, are known to be altered in severe heart failure
[23]. ACLY is responsible for converting citrate into oxaloacetate
in the cytoplasm and, in the process, generates a molecule of
Acetyl-CoA which is utilized by ACC to produce Malonyl-CoA,
the substrate used for the generation of long chain fatty acids by
FAS. Real-time PCR revealed a significant upregulation in the
expression of all three of these genes in VAChT-mutant mice
(Figure 4). However, assessment of protein expression levels
using immunoblotting revealed no significant differences in the
protein levels of these enzymes between WT and VAChT mutant
mice (Figure 5).
Analysis of Transcriptional Alterations in Isoproterenol-
treated Hearts
It is not clear whether autonomic imbalance due to reduced
cholinergic tone has similar consequences to imbalance due to
increased sympathetic tone. To examine whether the alterations in
gene expression observed in the ventricles of VAChT KDHOM
mice were observed in a different model of cardiac dysfunction, we
chronically treated wild-type mice with isoproterenol to induce
cardiac remodeling. Isoproterenol-treated mice demonstrated a
significant increase in heart weight to tibia length ratio as
compared to saline-treated mice (Figure 6a). Furthermore,
isoproterenol-treated mice demonstrated a significant increase in
the expression of two markers of cardiac stress; namely, b-myosin
heavy chain (b-MHC: Figure 6b) and atrial natriuretic peptide
(ANP; Figure 6c). Next we examined potential changes in the
expression pattern of genes that displayed altered expression in the
VAChT KDHOM mice. Interestingly, most of the genes which
were altered in VAChT KDHOM mice were not significantly
altered in hearts obtained from isoproterenol-treated mice
(Figure 7). However, the expression of Ogdhl (Figure 7f) was
significantly decreased following chronic treatment with isopro-
terenol, similar to the transcriptional alterations observed in the
VAChT mutant mice. The expression of PnP and Pnp2 were not
significantly different between isoproterenol-treated and saline-
Figure 5. There are no alterations in the protein levels of enzymes involved in lipid biosynthesis. Immunoblotting analysis of ATP citrate
lyase (ACLY, panel a), Acetyl-CoA carboxylase (ACC; panel b) and fatty acid synthase (FAS; panel c) revealed no differences in the protein levels of
these enzymes in VAChT KDHOM mice. Data represent the mean 6 SEM, with n indicated within bars. *p,0.05 versus wild-type mice.
doi:10.1371/journal.pone.0039997.g005
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treated mice (Figure 8a, 8b), suggesting that alterations in these
genes are specifically related to a decrease in cholinergic tone.
In contrast to the transcriptional changes found in the
microarray experiments, the expression of genes related to the
lipid biosynthetic pathway did, in fact, appear to be similarly
altered in isoproterenol-treated mice and VAChT KDHOM mice
(Figure 8c, 8d, 8e). Furthermore, the relative change in the
expression of these genes was much larger in isoproterenol-treated
mice than that observed in VAChT KDHOM hearts. Hence, some,
but not all transcriptional alterations are reproduced between
isoproterenol-treated mice and VAChT KDHOM mice.
Discussion
Recent reports have implicated the parasympathetic nervous
system in the development and progression of heart failure as well
as being a potential therapeutic target in heart disease [24]. Vagal
stimulation can improve outcome in experimental heart failure [6]
and this can be mimicked by treatment with cholinesterase
inhibitors [8]. Our previous studies have demonstrated that mice
with a systemic decrease in cholinergic tone develop cardiac
dysfunction and exhibit many of the characteristics present in
cardiac remodeling [5]. Importantly, in VAChT KDHOM mice,
these cardiac defects are ameliorated by cholinesterase inhibitor
treatment, implicating release of ACh rather than developmen-
tally-induced changes in the control of heart function. Interest-
ingly, in heart failure, transdifferentiation of sympathetic neurons
into a cholinergic phenotype has recently been demonstrated, and
this appears to have a protective role [9]. However, the role of
acetylcholine in controlling long-term cardiac function is still
poorly understood.
The present study examined whether the decrease in parasym-
pathetic tone in VAChT KDHOM mice leads to alterations in
cardiac gene expression which may contribute to the observed
cardiac dysfunction. Our microarray analysis revealed a number
of transcriptional changes with a total of 71 genes being
significantly different between these mice. Interestingly, transcript
and protein levels of two purine nucleoside phosphorylases (Pnp
and Pnp2) were significantly increased in the VAChT mutant
mice. Both Pnp and Pnp2 are important enzymes responsible for
the conversion of inosine to hypoxanthine and have also been
shown to metabolize adenosine into adenine, especially under
conditions of cardiac stress [12,25,26].
The increased levels of Pnp and Pnp2 in VAChT KDHOM mice
may lead to the increased production of hypoxanthine in mutant
hearts [12]. Interestingly, endothelial cells in the heart appear to
be responsible for the majority of adenosine uptake [27]. In
addition, they are responsible for the metabolism of adenosine into
several compounds, including hypoxanthine [28]. Increased levels
of this adenosine metabolite may serve a key role in the cardiac
Figure 6. Chronic treatment with isoproterenol (ISO)-induces cardiac remodeling in wild-type mice. Two week ISO treatment led to a
significant increase in heart weight/tibia length ratio as compared to saline-treated control mice (panel a). The expression of b-myosin heavy chain
(b-MHC, panel b) and atrial natriuretic factor (ANF, panel c) were significantly upregulated in ISO-treated mice. Data represent the mean 6 SEM,
with n indicated within bars. *p,0.05 versus wild-type mice.
doi:10.1371/journal.pone.0039997.g006
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dysfunction observed in mutant mice. For example, hypoxanthine,
produced in endothelial cells, can be taken up by the ENT and
ENBT1 transporters into myocytes [13,14], where it can be
further metabolized into xanthine and urate [12]. These
metabolites contribute to the production of ROS [15,16,17,18],
increased levels of which have been shown to play a role in cardiac
and vascular dysfunction in both ischemic and non-ischemic
cardiomyopathies [16,18,29,30]. Interestingly, we observed an
increase in the levels of ROS in ventricular cardiomyocytes
isolated from VAChT KDHOM mice. Oxygen free radicals
contribute to declining cardiac function during heart failure via
many different mechanisms and result in damage to the
myocardium [31,32]. They can also have detrimental effects
specifically in cardiomyocytes as they can activate cell death
through both necrotic and apoptotic pathways [33,34]. Future
studies will be necessary to further characterize the mechanisms
which lead to increased ROS production in the mutant mice as
well as determine the physiological importance of these oxygen
free radicals and their role in the observed cardiac dysfunction.
Figure 7. ISO treatment does not lead to the same transcriptional alterations observed in VAChT KDHOM mice. mRNA expression of
tRNA splicing endonuclease 3 (Tsen15; panel a), Growth arrest specific 5 (Gas5; panel b), karyopherin alpha 2 (Kpna2; panel c), suppressor of
cytokine signaling 4 (Socs4; panel d), ribonuclease, RNase A family 4 (Rnase4; panel e) and oxoglutarate-dehydrogenase like (Ogdhl; panel f) were
not significantly altered in the ISO-treated mice as compared to saline-treated controls. Data represent the mean6 SEM, with n indicated within bars.
*p,0.05 versus wild-type mice.
doi:10.1371/journal.pone.0039997.g007
Heart mRNA Analysis under Reduced Cholinergic Tone
PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e39997
However, it is tempting to speculate that these alterations may play
a role in the dysfunction found in VAChT mutant mice.
It is important to note that ADP levels are upregulated in heart
failure suggesting that failing cardiac tissue utilizes greater
amounts of ATP [35]. Under normal conditions, the vasodilatory
actions of adenosine may be able to compensate for this increased
utilization of ATP by myocardial tissue. However, VAChT
KDHOM mice show increased levels of Pnp which has previously
been shown to metabolize adenosine into adenine [25,26]. This
may contribute to the inability of the mutant hearts to maintain
normal contractile function; an idea which is in accordance with
previous research suggesting that the failing heart is energy-starved
[36,37]. It should be noted that these alterations seems to be
selectively related to decreased cholinergic function, as the changes
observed in the microarray experiments were not observed in
isoproterenol-treated mice.
Significant alterations in substrate metabolism have been
observed during the progression of heart failure and it is suggested
Figure 8. Expression of genes related to fatty acid synthesis is increased following isoproterenol (ISO) treatment. mRNA expression of
purine nucleoside phosphrylases (Pnp and Pnp2; panels a and panel b) were not altered following ISO treatment. ATP citrate lyase (ACLY; panel c),
acetyl-CoA carboxylase (ACC; panel d) and fatty acid synthase (FAS; panel e) expression were all significantly increased in ISO-treated mice as
compared to saline-treated controls. Data represent the mean 6 SEM, with n indicated within bars. *p,0.05 versus wild-type mice.
doi:10.1371/journal.pone.0039997.g008
Heart mRNA Analysis under Reduced Cholinergic Tone
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that these changes contribute to cardiac remodeling and
dysfunction observed during disease progression [38]. Previous
studies have shown that, in end stage heart failure, there is an
increase in glucose oxidation coupled with a decrease in fatty acid
oxidation and these changes in substrate utilization lead to adverse
effects during late stage heart failure [19,20,21,22].
To further examine transcriptional alterations in VAChT
mutant hearts that may not have been identified in the microarray,
we chose genes related to the lipid biosynthetic pathway (ACLY,
ACC and FAS). These pathways have been previously found to be
altered in heart failure [23]. In agreement with the notion in
cardiac dysfunction these pathways may be altered, chronic
treatment with the b-agonist isoproterenol, which mimics the
sympathetic overactivation observed in several cardiac diseases,
increased mRNA levels for ACLY, ACC and FAS several fold. We
also found an increase in mRNA expression of ACLY, ACC and
FAS in VAChT mutant mice, suggesting at least some similarities
between autonomic imbalance due to decreased cholinergic tone
and sympathetic overactivation. Although gene expression chang-
es were confirmed for several genes involved in the generation of
long-chain fatty acids in VAChT-mutant mice, the protein levels
for these enzymes appeared to be unaltered, although we cannot
discard the possibility that their turnover might be increased.
It is important to note that VAChT KDHOM animals exhibit a
global decrease in VAChT levels and, therefore, decreased
cholinergic tone. This is significant because it has recently been
proposed that cardiomyocytes possess the machinery (VAChT,
ChAT and CHT1) for de novo production of ACh [39,40] and are
able to synthesize and release this neurotransmitter. This non-
neuronal ACh may then act in an autocrine/paracrine fashion to
amplify neuronal cholinergic signaling [40]. We have recently
demonstrated that this non-neuronal cardiomyocyte release of
ACh plays an important role in the protection of myocytes against
isoproterenol-induced hypertrophy and that VAChT mutant mice
are deficient in non-neuronal ACh secretion as well [41]. We
cannot discard the possibility that the gene alterations we
uncovered here may, at least in part, be due to deficient ACh
release from cardiomyocytes. Future studies will be necessary to
specifically analyze the importance of this non-neuronal cholin-
ergic system in myocytes and its contribution to the cardiac
dysfunction observed after reduced cholinergic tone. This may
provide an unanticipated mechanism by which non-neuronal ACh
can play an important role in cardiac function.
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